Paysign’s (PAYS) “Outperform” Rating Reiterated at Barrington Research

Paysign (NASDAQ:PAYS)‘s stock had its “outperform” rating reiterated by stock analysts at Barrington Research in a report issued on Wednesday,Benzinga reports. They currently have a $7.00 price target on the stock. Barrington Research’s target price would suggest a potential upside of 182.26% from the company’s current price.

Separately, Lake Street Capital assumed coverage on shares of Paysign in a report on Friday, December 20th. They issued a “buy” rating and a $6.00 target price for the company.

Paysign Price Performance

Shares of PAYS stock opened at $2.48 on Wednesday. The firm has a market capitalization of $132.80 million, a price-to-earnings ratio of 16.53 and a beta of 0.93. The business has a fifty day moving average of $2.67 and a 200 day moving average of $3.25. Paysign has a 1 year low of $2.25 and a 1 year high of $5.59.

Paysign (NASDAQ:PAYS) last issued its quarterly earnings results on Tuesday, March 25th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. As a group, equities research analysts expect that Paysign will post 0.21 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Topline Capital Management, Ll sold 231,187 shares of the company’s stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $3.31, for a total transaction of $765,228.97. Following the completion of the transaction, the insider now owns 5,859,046 shares of the company’s stock, valued at approximately $19,393,442.26. This represents a 3.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Topline Capital Partners, Lp sold 154,982 shares of Paysign stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $3.06, for a total value of $474,244.92. Following the completion of the transaction, the insider now directly owns 5,456,146 shares in the company, valued at $16,695,806.76. This represents a 2.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 927,087 shares of company stock valued at $2,872,039. Corporate insiders own 23.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PAYS. Barclays PLC boosted its holdings in shares of Paysign by 327.4% in the 3rd quarter. Barclays PLC now owns 47,090 shares of the company’s stock valued at $173,000 after buying an additional 36,071 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Paysign by 164.1% in the third quarter. JPMorgan Chase & Co. now owns 63,247 shares of the company’s stock worth $232,000 after purchasing an additional 39,299 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Paysign by 257.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 44,793 shares of the company’s stock valued at $164,000 after buying an additional 32,245 shares during the period. Sanctuary Advisors LLC raised its holdings in Paysign by 4.3% during the third quarter. Sanctuary Advisors LLC now owns 121,089 shares of the company’s stock worth $419,000 after purchasing an additional 5,000 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Paysign by 33.5% in the 4th quarter. SG Americas Securities LLC now owns 15,508 shares of the company’s stock worth $47,000 after buying an additional 3,895 shares in the last quarter. 25.89% of the stock is currently owned by institutional investors.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.